Literature DB >> 18312854

MHC class I and integrin ligation induce ERK activation via an mTORC2-dependent pathway.

Peter T Jindra1, Yi-Ping Jin, Rodrigo Jacamo, Enrique Rozengurt, Elaine F Reed.   

Abstract

The aim of this study was to characterize the interaction between mTOR and ERK in primary endothelial cells (EC) following MHC class I and integrin ligation. Ligation of MHC class I molecules or integrins on the surface of EC leads to phosphorylation of ERK at Thr202/Tyr204. We utilized small interfering RNA (siRNA) blockade of mTOR and proteins involved in mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2) to define a relationship between mTOR and ERK following MHC class I signaling. We found mTORC2 was responsible for MHC class I and integrin induced phosphorylation of ERK at Thr202/Tyr204. We corroborated these results demonstrating that long-term exposure to rapamycin also inhibited ERK pathway activation in response to MHC class I signaling. Our results demonstrate, for the first time, that engagement of either MHC class I or integrin on the surface of EC leads to ERK activation through an mTORC2-dependent pathway.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18312854      PMCID: PMC2376207          DOI: 10.1016/j.bbrc.2008.02.093

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  34 in total

Review 1.  Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention.

Authors:  F Chang; L S Steelman; J T Lee; J G Shelton; P M Navolanic; W L Blalock; R A Franklin; J A McCubrey
Journal:  Leukemia       Date:  2003-07       Impact factor: 11.528

2.  Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action.

Authors:  Kenta Hara; Yoshiko Maruki; Xiaomeng Long; Ken-ichi Yoshino; Noriko Oshiro; Sujuti Hidayat; Chiharu Tokunaga; Joseph Avruch; Kazuyoshi Yonezawa
Journal:  Cell       Date:  2002-07-26       Impact factor: 41.582

3.  Beta 1/beta 3 integrin ligation is uncoupled from ERK1/ERK2 activation in cytotoxic T lymphocytes.

Authors:  Lawrence G Puente; Hanne L Ostergaard
Journal:  J Leukoc Biol       Date:  2003-03       Impact factor: 4.962

4.  Increased transcription of IL-8 in endothelial cells is differentially regulated by TNF-alpha and oxidized phospholipids.

Authors:  M Yeh; N Leitinger; R de Martin; N Onai; K Matsushima; D K Vora; J A Berliner; S T Reddy
Journal:  Arterioscler Thromb Vasc Biol       Date:  2001-10       Impact factor: 8.311

5.  The mammalian target of rapamycin (mTOR) partner, raptor, binds the mTOR substrates p70 S6 kinase and 4E-BP1 through their TOR signaling (TOS) motif.

Authors:  Hiroki Nojima; Chiharu Tokunaga; Satoshi Eguchi; Noriko Oshiro; Sujuti Hidayat; Ken-ichi Yoshino; Kenta Hara; Noriaki Tanaka; Joseph Avruch; Kazuyoshi Yonezawa
Journal:  J Biol Chem       Date:  2003-02-25       Impact factor: 5.157

6.  mTOR is essential for growth and proliferation in early mouse embryos and embryonic stem cells.

Authors:  Mirei Murakami; Tomoko Ichisaka; Mitsuyo Maeda; Noriko Oshiro; Kenta Hara; Frank Edenhofer; Hiroshi Kiyama; Kazuyoshi Yonezawa; Shinya Yamanaka
Journal:  Mol Cell Biol       Date:  2004-08       Impact factor: 4.272

7.  Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton.

Authors:  D D Sarbassov; Siraj M Ali; Do-Hyung Kim; David A Guertin; Robert R Latek; Hediye Erdjument-Bromage; Paul Tempst; David M Sabatini
Journal:  Curr Biol       Date:  2004-07-27       Impact factor: 10.834

8.  PRR5, a novel component of mTOR complex 2, regulates platelet-derived growth factor receptor beta expression and signaling.

Authors:  So-Yon Woo; Dong-Hwan Kim; Chang-Bong Jun; Young-Mi Kim; Emilie Vander Haar; Seong-il Lee; James W Hegg; Sricharan Bandhakavi; Timothy J Griffin; Do-Hyung Kim
Journal:  J Biol Chem       Date:  2007-06-28       Impact factor: 5.157

9.  Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients.

Authors:  Howard J Eisen; E Murat Tuzcu; Richard Dorent; Jon Kobashigawa; Donna Mancini; Hannah A Valantine-von Kaeppler; Randall C Starling; Keld Sørensen; Manfred Hummel; Joan M Lind; Kamal H Abeywickrama; Peter Bernhardt
Journal:  N Engl J Med       Date:  2003-08-28       Impact factor: 91.245

10.  Fibronectin fragments promote human retinal endothelial cell adhesion and proliferation and ERK activation through alpha5beta1 integrin and PI 3-kinase.

Authors:  Sylvia H Wilson; Alexander V Ljubimov; Alex O Morla; Sergio Caballero; Lynn C Shaw; Polyxenie E Spoerri; Roy W Tarnuzzer; Maria B Grant
Journal:  Invest Ophthalmol Vis Sci       Date:  2003-04       Impact factor: 4.799

View more
  22 in total

1.  A novel pathway of chronic allograft rejection mediated by NK cells and alloantibody.

Authors:  T Hirohashi; C M Chase; P Della Pelle; D Sebastian; A Alessandrini; J C Madsen; P S Russell; R B Colvin
Journal:  Am J Transplant       Date:  2011-11-09       Impact factor: 8.086

2.  Antibody ligation of human leukocyte antigen class I molecules stimulates migration and proliferation of smooth muscle cells in a focal adhesion kinase-dependent manner.

Authors:  Fang Li; Xiaohai Zhang; Yi-Ping Jin; Arend Mulder; Elaine F Reed
Journal:  Hum Immunol       Date:  2011-10-01       Impact factor: 2.850

3.  HLA class I molecules partner with integrin β4 to stimulate endothelial cell proliferation and migration.

Authors:  Xiaohai Zhang; Enrique Rozengurt; Elaine F Reed
Journal:  Sci Signal       Date:  2010-11-23       Impact factor: 8.192

Review 4.  Translational implications of endothelial cell dysfunction in association with chronic allograft rejection.

Authors:  Sarah Bruneau; Johannes Wedel; Fadi Fakhouri; Hironao Nakayama; Leo Boneschansker; Daniel Irimia; Kevin P Daly; David M Briscoe
Journal:  Pediatr Nephrol       Date:  2015-04-24       Impact factor: 3.714

Review 5.  The link between major histocompatibility complex antibodies and cell proliferation.

Authors:  Nicole M Valenzuela; Elaine F Reed
Journal:  Transplant Rev (Orlando)       Date:  2011-07-30       Impact factor: 3.943

Review 6.  Chronic allograft rejection: a fresh look.

Authors:  Johannes Wedel; Sarah Bruneau; Nora Kochupurakkal; Leo Boneschansker; David M Briscoe
Journal:  Curr Opin Organ Transplant       Date:  2015-02       Impact factor: 2.640

7.  CD31 exhibits multiple roles in regulating T lymphocyte trafficking in vivo.

Authors:  Liang Ma; Kenneth C P Cheung; Madhav Kishore; Sussan Nourshargh; Claudio Mauro; Federica M Marelli-Berg
Journal:  J Immunol       Date:  2012-09-10       Impact factor: 5.422

8.  Antibodies to HLA Molecules Mimic Agonistic Stimulation to Trigger Vascular Cell Changes and Induce Allograft Injury.

Authors:  Nicole M Valenzuela; Elaine F Reed
Journal:  Curr Transplant Rep       Date:  2015-05-24

Review 9.  Roles of mTOR complexes in the kidney: implications for renal disease and transplantation.

Authors:  Daniel Fantus; Natasha M Rogers; Florian Grahammer; Tobias B Huber; Angus W Thomson
Journal:  Nat Rev Nephrol       Date:  2016-08-01       Impact factor: 28.314

10.  Everolimus inhibits anti-HLA I antibody-mediated endothelial cell signaling, migration and proliferation more potently than sirolimus.

Authors:  Y-P Jin; N M Valenzuela; M E Ziegler; E Rozengurt; E F Reed
Journal:  Am J Transplant       Date:  2014-03-01       Impact factor: 8.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.